340 related articles for article (PubMed ID: 19687456)
1. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
2. The challenge of follow-on biologics for treatment of multiple sclerosis.
Rivera VM
Neurology; 2010 Mar; 74(10):864. PubMed ID: 20211915
[No Abstract] [Full Text] [Related]
3. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
4. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
[TBL] [Abstract][Full Text] [Related]
5. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
7. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
Looper YJ
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
9. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
10. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
11. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
12. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
Paradise J
Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
14. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
Hennessy S; Leonard CE; Platt R
Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
[TBL] [Abstract][Full Text] [Related]
15. Characterizing biological products and assessing comparability following manufacturing changes.
Chirino AJ; Mire-Sluis A
Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
[TBL] [Abstract][Full Text] [Related]
16. Scientific and regulatory considerations on the immunogenicity of biologics.
Shankar G; Shores E; Wagner C; Mire-Sluis A
Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
[TBL] [Abstract][Full Text] [Related]
17. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
Tremaine WJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
[TBL] [Abstract][Full Text] [Related]
18. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
19. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
20. Development of probiotics as biologic drugs.
Hoffman FA
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
